About Labcorp Drug Development
Labcorp Drug Development is a division of Labcorp that provides comprehensive AI and real-world data solutions for the biopharma industry. The company operates at the intersection of diagnostic laboratory services and advanced analytics, offering data-driven insights that span from drug discovery through commercialization. With access to 45 billion diagnostic test results annually from 175 million patient encounters, Labcorp maintains one of the world's most extensive healthcare datasets. Their AI capabilities include predictive analytics for patient recruitment, pharmacokinetics modeling, fraud detection, natural language processing, and optical character recognition tools. The company supports over 5,100 clinical protocols and works with 186,000+ clinical investigator sites worldwide. Their solutions address critical challenges in drug development including protocol design, feasibility analytics, patient identification, and trial optimization. Labcorp's AI-powered platform, developed in partnership with Amazon Web Services (AWS) and Datavant, delivers longitudinal laboratory data with advanced analytics capabilities. The company serves pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) with HIPAA-compliant, de-identified, ethically sourced data. Their therapeutic focus areas include neurology (particularly Alzheimer's disease), immunology, oncology, rare diseases, and cardiovascular conditions. All data solutions maintain regulatory-grade quality standards to support evidence generation for regulatory submissions and market access decisions.
Clinical Focus
Medical conditions and clinical areas addressed by Labcorp Drug Development.
Who It Serves
Milestones & Awards
Recent Milestones
Launched AI-powered real-world data platform for Alzheimer's disease in partnership with AWS and Datavant
Key Partnerships
Social & Media
Latest Updates
Gail Bromage
Biocompatibility evaluation of implantable medical devices
Delivering precision in a critical bone defect model for implantable device safety testing
From complexity to clarity: Making sense of mosaic variants and preliminary evidence genes
Beyond traditional immunoassay: LC-MS for antibody isotyping and quantitation
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.